MYIA
XENE icon

Mount Yale Investment Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Mount Yale Investment Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,015
Closed -$31.8K – 1626
2025
Q2 		$31.8K Buy
+1,015
New +$33.1K ﹤0.01% 940

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Mount Yale Investment Advisors's XENE Position: Q3 2025 in Review

Mount Yale Investment Advisors sold out of Xenon Pharmaceuticals (XENE) in Q3 2025, closing a stake of 1,015 shares — an estimated $31.8K sold.

Mount Yale Investment Advisors first reported a position in XENE in Q2 2025 and held it in 1 quarter. The position peaked at $31.8K in Q2 2025. 219 funds tracked by Wall St. Rank hold XENE as of Q3 2025.

  • Mount Yale Investment Advisors reported no remaining Xenon Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Mount Yale Investment Advisors sold 1,015 Xenon Pharmaceuticals shares in Q3 2025, an estimated $31.8K.
  • Mount Yale Investment Advisors first reported a position in Xenon Pharmaceuticals in Q2 2025 and held it in 1 quarter.
  • Mount Yale Investment Advisors's Xenon Pharmaceuticals position peaked at $31.8K in Q2 2025.
  • 219 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q3 2025.

Based on Mount Yale Investment Advisors's 13F filing for Q3 2025, filed 14 Nov 2025.